TY - JOUR T1 - Assessment of Disease Severity in Late Infantile Neuronal Ceroid Lipofuscinosis Using Multiparametric MR Imaging JF - American Journal of Neuroradiology JO - Am. J. Neuroradiol. SP - 884 LP - 889 DO - 10.3174/ajnr.A3297 VL - 34 IS - 4 AU - J.P. Dyke AU - D. Sondhi AU - H.U. Voss AU - D.C. Shungu AU - X. Mao AU - K. Yohay AU - S. Worgall AU - N.R. Hackett AU - C. Hollmann AU - M.E. Yeotsas AU - A.L. Jeong AU - B. Van de Graaf AU - I. Cao AU - S.M. Kaminsky AU - L.A. Heier AU - K.D. Rudser AU - M.M. Souweidane AU - M.G. Kaplitt AU - B. Kosofsky AU - R.G. Crystal AU - D. Ballon Y1 - 2013/04/01 UR - http://www.ajnr.org/content/34/4/884.abstract N2 - BACKGROUND AND PURPOSE: LINCL is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene that encodes for tripeptidyl peptidase 1, a lysosomal enzyme necessary for the degradation of products of cellular metabolism. With the goal of developing quantitative noninvasive imaging biomarkers sensitive to disease progression, we evaluated a 5-component MR imaging metric and tested its correlation with a clinically derived disease-severity score. MATERIALS AND METHODS: MR imaging parameters were measured across the brain, including quantitative measures of the ADC, FA, nuclear spin-spin relaxation times (T2), volume percentage of CSF (%CSF), and NAA/Cr ratios. Thirty MR imaging datasets were prospectively acquired from 23 subjects with LINCL (2.5–8.4 years of age; 8 male/15 female). Whole-brain histograms were created, and the mode and mean values of the histograms were used to characterize disease severity. RESULTS: Correlation of single MR imaging parameters against the clinical disease-severity scale yielded linear regressions with R2 ranging from 0.25 to 0.70. Combinations of the 5 biomarkers were evaluated by using PCA. The best combination included ADC, %CSF, and NAA/Cr (R2 = 0.76, P < .001). CONCLUSIONS: The multiparametric disease-severity score obtained from the combination of ADC, %CSF, and NAA/Cr whole-brain MR imaging techniques provided a robust measure of disease severity, which may be useful in clinical therapeutic trials of LINCL in which an objective assessment of therapeutic response is desired. FAfractional anisotropyGMgray matterLINCLlate infantile neuronal ceroid lipofuscinosisMRIDSSMR imaging disease-severity scorePCAprincipal component analysis ER -